Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Period	fcf
2015-12-31	$445.60M
2016-12-31	$451.40M
2017-12-31	$784.50M
2018-12-31	$690.80M
2019-12-31	$873.70M
2020-12-31	$606.40M
2021-12-31	$1.40B
2022-12-31	$953.40M
2023-12-31	$629.50M
2024-12-31	$259.90M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EW	$81.05	+0.00%	3.30M
3
4
5

Edwards Lifesciences Corporation (EW) Free Cash Flow

Free Cash Flow Data

Get Edwards Lifesciences Corporation Data in Excel

More EW Financial Data